Advertisement

Patents Expire for Big Name Drugs

As seven of the world’s top selling drugs expire over the next year, prescription prices are set to drop while generics fill in.

By | July 25, 2011

WIKIMEDIA COMMONS, TOM VARCO

Between now and October 2012, the patents for seven big name drugs will expire, including those for a popular cholesterol lowering drug, Lipitor, and the blood thinner Plavix. In addition, the next five years will see the patent expiration for drugs that currently bring in about $255 billion each year in global sales, according to London research firm EvaluatePharma.

The generic drugs that will pop up as the big name patents expire will mark an unprecedented change in the market, reports The Seattle Times. In the next decade, about 120 brand-name prescription drugs for high cholesterol, blood pressure, asthma, diabetes, depression, high triglycerides, HIV, bipolar disorder, and more will find themselves up against cheaper generic versions, which cost anywhere from 20 to 80 percent less than their brand name competitors.

"My estimation is at least 15 percent of the population is currently using one of the drugs whose patents will expire in 2011 or 2012," Joel Owerbach, chief pharmacy officer for Excellus Blue Cross Blue Shield, told The Times.

For those who aren’t filling their prescriptions because they can’t afford them, the change may bring welcome relief. But for drug makers, which have failed to keep up the blockbuster pace of the 1990s, it could mean disaster.

"The profit dollars that companies used to reinvest in innovation are no longer going to be coming," says Terry Hisey, a consultant at Deloitte told The Times, which raises "long-term concerns about the industry's ability to bring new medicines to market."

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Poatoday

Anonymous

July 26, 2011

Baloney that price drops threaten R&D. These companies spend far more on advertising than R&D.

Avatar of:

Posts: 0

July 26, 2011

Baloney that price drops threaten R&D. These companies spend far more on advertising than R&D.

Avatar of:

Posts: 0

July 26, 2011

Baloney that price drops threaten R&D. These companies spend far more on advertising than R&D.

Avatar of:

Posts: 0

July 27, 2011

Thanks for that. It's sickening how many "ask your doctor" commercials are on nowadays. Between big Pharma and Insurance companies that's about all you see.

Avatar of:

Posts: 0

July 27, 2011

Thanks for that. It's sickening how many "ask your doctor" commercials are on nowadays. Between big Pharma and Insurance companies that's about all you see.

Avatar of: Anaxpb

Anonymous

July 27, 2011

Thanks for that. It's sickening how many "ask your doctor" commercials are on nowadays. Between big Pharma and Insurance companies that's about all you see.

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
Ingenuity Systems
Ingenuity Systems

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
R&D Systems
R&D Systems
Advertisement